Health in Centenarians

Rasmussen, Signe Hoei; Andersen-Ranberg, Karen

doi:10.1007/978-981-287-080-3_78-2

Cited by 2 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Half a year before death, our sample showed an overall AF prevalence of 28.7% across all age groups and 22.4% in the group of centenarians. Both the general level of AF prevalence in very old patients as well as the lower prevalence in centenarians compared with younger cohorts is in line with other findings described in the literature. Conversely, 6 years before death, the AF rates in the present sample were lower with 9% across all age groups and 6.3% in centenarians than the average rates mentioned in the literature .…”

Section: Discussionsupporting

confidence: 91%

“…Both the general level of AF prevalence in very old patients as well as the lower prevalence in centenarians compared with younger cohorts is in line with other findings described in the literature. Conversely, 6 years before death, the AF rates in the present sample were lower with 9% across all age groups and 6.3% in centenarians than the average rates mentioned in the literature . Furthermore, we found that the prevalence of AF in centenarians did not rise towards the end of life as steeply as in other age groups, which might reflect the fact that centenarians compress AF during the last years of life …”

Section: Discussioncontrasting

confidence: 83%

“…A meta‐analysis of AF prevalence showed increasing rates of AF with each decade, yet a drop of AF prevalence in centenarians . In previous reports, prevalence estimates of AF in centenarian studies varied from 0% to 30% across surveys, whereas in more recent studies the range was narrower, between 12% and 30% …”

Section: Introductionmentioning

confidence: 94%

See 2 more Smart Citations

Atrial fibrillation and medication treatment among centenarians: Are all very old patients treated the same?

Kreutz

Schmidt

Dräger

et al. 2018

Geriatrics Gerontology Int

View full text Add to dashboard Cite

Aim Evidence on antithrombotic therapy use in centenarians diagnosed with atrial fibrillation (AF) is sparse. Our objective was to investigate a possible underprescribing in centenarians relative to younger cohorts of the oldest‐old. We assumed lower AF rates; and, within AF patients, lower use of anticoagulants in those who died as centenarians (aged ≥100 years) than in those who died aged in their 80s (≥80 years) or 90s (≥90 years). Methods The present study was a quarterly structured cohort study over the 6 years before death using administrative data from German institutionalized and non‐institutionalized insured patients (whole sample n = 1398 and subsample of AF patients n = 401 subclassified according to age‐of‐death groups [≥80, ≥90, ≥100 years]). AF, medication, stroke risk (Congestive heart failure; Hypertension; 2 × Age ≥75 years; Diabetes mellitus; 2 × Stroke; Vascular disease; Age 65–74 years; Sex [female] (CHA2DS2‐VASc)) and risk of major bleeding (Hypertension; Abnormal renal and liver function; Stroke; Bleeding; Labile International Normalized Ratio [omitted in the present analysis]; Elderly; Drugs or alcohol (HAS‐BLED)) were calculated. Generalized estimation equations were used to model the trajectories. Results Half a year before death (T1), AF rates were higher in patients aged ≥80 years (31.8%) and ≥90 years (30.6%) compared with patients aged ≥100 years (22.4%), whereas there were no significant differences between age groups 6 years before death (T0). Of all AF patients with AF at T1, 26.7% received anticoagulants; 11.2% vitamin K antagonists; 15.7% non‐vitamin K antagonist oral anticoagulants; and 17.5% platelet inhibitors; yet 58.1% received none of these drugs. Centenarians received significantly fewer anticoagulants compared with the other age groups. Prescriptions of anticoagulants were not associated with CHA2DS2‐VASc with and without adjustment for HAS‐BLED. Conclusions The present findings highlight the need for more appropriate use of anticoagulation therapy in older patients, as well as for new treatment guidelines taking the heterogeneity of very old patients into account. Geriatr Gerontol Int 2018; 18: 1634–1640.

show abstract

Section: Discussionsupporting

confidence: 91%